Search research articles
Contact Us
Filters
Showing results (11-20 of 189) with videos related to
Page
of 19
Sort By:
Advances in Pharmacology (San Diego, Calif.)
|
July 4, 2020
Ketamine for depression clinical issues
Syed Z Iqbal, Sanjay J Mathew
The Mount Sinai Journal of Medicine, New York
|
August 16, 2008
Anxiety disorders: a comprehensive review of pharmacotherapies
Ellen J Hoffman, Sanjay J Mathew
The American Journal of Psychiatry
|
February 4, 2020
Ketamine Plus Motivational Enhancement Therapy: Leveraging a Rapid Effect to Promote Enduring Change
Sanjay J Mathew, Rebecca B Price
The American Journal of Psychiatry
|
March 1, 2023
Pharmacotherapies for Treatment-Resistant Depression: How Antipsychotics Fit in the Rapidly Evolving Therapeutic Landscape
Manish K Jha, Sanjay J Mathew
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
|
July 17, 2023
The why, when, where, how, and so what of so-called rapidly acting antidepressants
Alan F Schatzberg, Sanjay J Mathew
Chronic Stress (Thousand Oaks, Calif.)
|
July 6, 2019
"Does the opioid system block or enhance the antidepressant effects of ketamine?"
Sanjay J Mathew, Ana Maria Rivas-Grajales
Revista Brasileira De Psiquiatria (Sao Paulo, Brazil : 1999)
|
October 15, 2005
Glutamate modulators as novel interventions for mood disorders
Sanjay J Mathew, Kathryn Keegan, Lisa Smith
The New England Journal of Medicine
|
September 6, 2023
Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression. Reply
Amit Anand, Sanjay J Mathew, Bo Hu
Expert Opinion on Drug Safety
|
March 7, 2022
A comparison of the safety, feasibility, and tolerability of ECT and ketamine for treatment-resistant depression
Amanda Tamman, Amit Anand, Sanjay J Mathew
The Mount Sinai Journal of Medicine, New York
|
January 2, 2007
Neurobiology of anxiety disorders and implications for treatment
Amir Garakani, Sanjay J Mathew, Dennis S Charney
Page
of 19
Search research articles
Search
Showing results (11-20 of 189) with videos related to
Sort By:
Page
of 19
Advances in Pharmacology (San Diego, Calif.)
|
July 4, 2020
Ketamine for depression clinical issues
Syed Z Iqbal, Sanjay J Mathew
The Mount Sinai Journal of Medicine, New York
|
August 16, 2008
Anxiety disorders: a comprehensive review of pharmacotherapies
Ellen J Hoffman, Sanjay J Mathew
The American Journal of Psychiatry
|
February 4, 2020
Ketamine Plus Motivational Enhancement Therapy: Leveraging a Rapid Effect to Promote Enduring Change
Sanjay J Mathew, Rebecca B Price
The American Journal of Psychiatry
|
March 1, 2023
Pharmacotherapies for Treatment-Resistant Depression: How Antipsychotics Fit in the Rapidly Evolving Therapeutic Landscape
Manish K Jha, Sanjay J Mathew
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
|
July 17, 2023
The why, when, where, how, and so what of so-called rapidly acting antidepressants
Alan F Schatzberg, Sanjay J Mathew
Chronic Stress (Thousand Oaks, Calif.)
|
July 6, 2019
"Does the opioid system block or enhance the antidepressant effects of ketamine?"
Sanjay J Mathew, Ana Maria Rivas-Grajales
Revista Brasileira De Psiquiatria (Sao Paulo, Brazil : 1999)
|
October 15, 2005
Glutamate modulators as novel interventions for mood disorders
Sanjay J Mathew, Kathryn Keegan, Lisa Smith
The New England Journal of Medicine
|
September 6, 2023
Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression. Reply
Amit Anand, Sanjay J Mathew, Bo Hu
Expert Opinion on Drug Safety
|
March 7, 2022
A comparison of the safety, feasibility, and tolerability of ECT and ketamine for treatment-resistant depression
Amanda Tamman, Amit Anand, Sanjay J Mathew
The Mount Sinai Journal of Medicine, New York
|
January 2, 2007
Neurobiology of anxiety disorders and implications for treatment
Amir Garakani, Sanjay J Mathew, Dennis S Charney
Page
of 19